SCHEMBL19260416

SCHEMBL19260416

C#Cc1ccc(CCCCO)nc1

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.39
ACACB O00763 1/20 0.33
EGLN1 Q9GZT9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30998248 0.87 FFAR1 (0.41) FFAR1ACACBEGLN1
SCHEMBL12750934 0.81 KCNH2 (0.44) FFAR1ACACB
SCHEMBL3010045 0.80 FFAR1 (0.37) FFAR1ACACBEGLN1
SCHEMBL19260413 0.77 FFAR1 (0.37) FFAR1ACACB
SCHEMBL503735 0.77 HRH1 (0.42) FFAR1ACACB
SCHEMBL19113961 0.77 FFAR1 (0.38) FFAR1ACACB
SCHEMBL20436993 0.74 ESR1 (0.43)
SCHEMBL3547047 0.73 ADRA2A (0.40)
SCHEMBL20099862 0.73 PDE10A (0.42)
SCHEMBL4768617 0.73 ADRA2A (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548899-B2 Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-01-10 US disclosed
US-11548899-B2 Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-01-10 US disclosed
US-11466028-B2 Fused 1,4-oxazepines as BET protein degraders THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2022-10-11 US disclosed
EP-3512855-B1 FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2022-07-27 EP disclosed
CN-110062759-B Fused 1, 4-oxazepine as BET protein degrading agent 密执安大学评议会 2022-05-24 CN disclosed
CN-109071562-B Fused 1, 4-oxazepine and related analogs as BET bromodomain inhibitors 密执安大学评议会 2022-03-22 CN disclosed
US-20210284657-A1 FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2021-09-16 US disclosed
US-20210284657-A1 FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2021-09-16 US disclosed
US-20210188870-A1 FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS UNIV MICHIGAN REGENTS (US) 2021-06-24 US disclosed
US-20210188870-A1 FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS UNIV MICHIGAN REGENTS (US) 2021-06-24 US disclosed
EP-3416969-B1 FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS UNIV MICHIGAN REGENTS (US) 2021-05-05 EP disclosed
EP-3416969-B1 FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS UNIV MICHIGAN REGENTS (US) 2021-05-05 EP disclosed
EP-3512855-A1 FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS The Regents of the University of Michigan (US) 2019-07-24 EP disclosed
EP-3416969-A1 FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS The Regents of The University of Michigan (US) 2018-12-26 EP disclosed
WO-2018052945-A1 FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2018-03-22 WO disclosed
WO-2018052945-A1 FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2018-03-22 WO disclosed
WO-2017142881-A1 FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-08-24 WO disclosed
WO-2017142881-A1 FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11466028-B2 Fused 1,4-oxazepines as BET protein degraders BRD4, BET1, BRD1 FFAR1 2895/4885ACACB 1444/4885EGLN1 1144/4885
US-20210188870-A1 FUSED 1,4-OXAZEPINES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 FFAR1 2753/4885ACACB 1258/4885EGLN1 2126/4885
US-11548899-B2 Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors BRD4, BRD3, BRD2 FFAR1 2753/4885ACACB 1258/4885EGLN1 2126/4885
US-20210284657-A1 FUSED 1,4-OXAZEPINES AS BET PROTEIN DEGRADERS BRD4, BET1, BRD1 FFAR1 2895/4885ACACB 1444/4885EGLN1 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.